- £198.21bn
- £217.54bn
- $54.07bn
- 85
- 16
- 86
- 71
REG - AstraZeneca PLC - Lynparza approved in Japan for BRCAm breast cancer
AnnouncementREG - AstraZeneca PLC - Imfinzi approved in Japan for Stage III nsclc
AnnouncementREG - AstraZeneca PLC - Bydureon receives positive CHMP opinion for BCise
AnnouncementREG - AstraZeneca PLC - AZ and Luye Pharma complete agreement for Seroquel
AnnouncementREG - AstraZeneca PLC - Lynparza: significant PFS 1st-line ovarian cancer
AnnouncementREG - AstraZeneca PLC - Board Committee Changes
AnnouncementREG - AstraZeneca PLC - Publication of a Prospectus
AnnouncementREG - AstraZeneca PLC - Update: lanabecestat Phase III Alzheimer's trials
AnnouncementREG - AstraZeneca PLC - EU APPROVES TAGRISSO FOR 1ST-LINE NSCLC
AnnouncementREG - AstraZeneca PLC - Director Declaration
AnnouncementREG - AstraZeneca PLC - Block listing Interim Review
AnnouncementREG - AstraZeneca PLC - Total Voting Rights
AnnouncementREG - AstraZeneca PLC - Director Declaration
AnnouncementREG - AstraZeneca PLC - Update on TERRANOVA PIII trial for Fasenra in COPD
AnnouncementREG - AstraZeneca PLC - AZ's Imfinzi: significant OS in Stage III nsclc
AnnouncementREG - AstraZeneca PLC - AZ regulatory submission in Japan for Forxiga
AnnouncementREG - AstraZeneca PLC - US FDA approves Lokelma for adult hyperkalaemia
AnnouncementREG - AstraZeneca PLC - Result of AGM
AnnouncementREG - AstraZeneca PLC - AZN: Q1 2018 Results
Announcement